List of Vivitrol drug patents
Vivitrol is owned by Alkermes.
Vivitrol contains Naltrexone.
Vivitrol has a total of 1 drug patent out of which 0 drug patents have expired.
Vivitrol was authorised for market use on 13 April, 2006.
Vivitrol is available in for suspension, extended release;intramuscular dosage forms.
Vivitrol can be used as prevention of relapse to opioid dependence, following opioid detoxification; treatment of alcohol dependence.
The generics of Vivitrol are possible to be released after 15 October, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919499 | ALKERMES | Naltrexone long acting formulations and methods of use |
Oct, 2029
(6 years from now) | |
Drugs and Companies using NALTREXONE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: Prevention of relapse to opioid dependence, following opioid detoxification; Treatment of alcohol dependence
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic